Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
about
Molecular testing to optimize therapeutic decision making in advanced colorectal cancerPersonalized treatment for advanced colorectal cancer: KRAS and beyondEGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysisPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesHER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer CellsMixed granular cell astrocytoma and fibrosarcoma of the brain: a case reportGenetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer.Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinomaEGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis.Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer.Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximabEGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer.Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximabPredicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering.A rare case of malignant pediatric ectomesenchymoma arising from the cerebrum.The status of epidermal growth factor receptor in borderline ovarian tumours.Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancerSomatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas.Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patientsStandardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies.Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx.
P2860
Q26749012-DAB7C4B7-C60A-43C1-8198-D1AD58AED207Q26822817-A8C8BCF9-7C1E-4642-B55D-717277B8D5C9Q26865056-A70B8A0C-8CFA-4DBB-9814-B65D9B3730C0Q27015224-547889CD-DBA6-419E-B0D2-AF269A67413AQ27852057-4B0D8DA6-221A-4742-B5C4-CF7AD7AEBCFEQ27852970-6D70FC97-121B-43C5-996A-5BF96CF516CBQ28534094-2178D739-702C-406A-A36F-5203A4908B00Q28654665-B0E459AA-50B6-4FE1-8033-E74E0E221E95Q33683680-26464E9C-E9C8-4381-9C36-B5523C34D302Q34064466-31098DDF-FB97-4446-834E-530F2E8C85A7Q34381843-D829E02D-C59C-43E8-8172-13140BE9C20CQ34498746-9275CB42-B87A-44EB-8914-BD207139E641Q34658903-96CC946C-9F10-42AA-939E-925824B2BBB1Q35034638-E56CCB1B-25B1-4D80-B4B7-954A655C2AB7Q35042323-00DC03D2-EDC5-46B8-9585-EA110F88C3A0Q35125640-3D8E1E73-973E-4BC1-96F5-A8E0AEF9103FQ35583697-29C5832E-B940-48D9-BFD8-8D26617A89D8Q35583889-AC3A9F44-BCAD-4299-8F71-8EB9BEC4ABFBQ35584314-EA96CD31-8C5D-4700-9024-5A54F7164B2DQ35954982-BEF46EEF-FD54-463D-9A21-37CD4985573AQ36014502-F52C4D70-58EA-495D-BABB-7047CAC83841Q36963030-FA4D8545-4EBD-47BF-BE2F-46009EEB64A6Q37133974-0FF2539F-E610-4AC7-B2C0-4DE8CBBDC1EFQ37146300-22F5A172-C43D-45B5-AC63-C7763FE45CE5Q37252262-6545245D-C031-44C0-BC1A-1286FCEC082AQ37817718-CC1B966D-ECEE-46EF-8E64-5090464FF488Q38166233-7F648FBF-1255-4C67-9B8E-AF3FCB71CC45Q38668967-DD282F79-C921-4DB1-BC51-097A2BF1DD18Q38815325-257067A6-7C5B-4109-9DF9-754CC26BB6EFQ39223563-F1E14F98-E51D-4FD7-866E-FD522CDB9568Q41410508-1C3DC020-CF99-4CD0-9D93-B71882B56845Q41511106-ED5E55FA-FD91-48AF-ABB7-E5D5FDFE1934Q42052616-D3522D0D-BB9F-466C-BED7-0B947E3D93AAQ43211029-48E4CD5A-BBC9-4EBE-AF74-260E000F34BFQ44649659-493395B9-1606-4D64-A2F4-42A8712410D5Q45203079-B930CB92-4883-4EF8-9272-76BE97B19596
P2860
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Epidermal Growth Factor Recept ...... hybridization (CISH) analysis.
@ast
Epidermal Growth Factor Recept ...... hybridization (CISH) analysis.
@en
type
label
Epidermal Growth Factor Recept ...... hybridization (CISH) analysis.
@ast
Epidermal Growth Factor Recept ...... hybridization (CISH) analysis.
@en
prefLabel
Epidermal Growth Factor Recept ...... hybridization (CISH) analysis.
@ast
Epidermal Growth Factor Recept ...... hybridization (CISH) analysis.
@en
P2093
P2860
P50
P356
P1433
P1476
Epidermal Growth Factor Recept ...... hybridization (CISH) analysis.
@en
P2093
Alberto Zaniboni
Alessandra Mandolesi
Antonello Quadri
Chiara Pierantoni
Eva Galizia
Fausto Zorzi
Francesca Negri
Gianluca Masi
Italo Bearzi
Tommasina Biscotti
P2860
P2888
P356
10.1186/1471-2407-9-303
P407
P577
2009-08-27T00:00:00Z
P5875
P6179
1048014790